Skip to main content

Boostrix FDA Approval History

FDA Approved: Yes (First approved May 3, 2005)
Brand name: Boostrix
Generic name: tetanus, diphtheria, acellular pertussis vaccine (Tdap)
Company: GlaxoSmithKline Biologicals
Treatment for: Diphtheria Prophylaxis, Tetanus Prophylaxis, Pertussis Prophylaxis

Boostrix is a combination vaccine that provides a booster immunization against pertussis (whooping cough) in combination with tetanus and diphtheria.

Development Timeline for Boostrix

Jul 11, 2011Approval  FDA approves Boostrix to prevent tetanus, diphtheria, and pertussis in older people
Dec 13, 2008Approval  FDA Approves GlaxoSmithKline Tetanus, Diphtheria, Whooping Cough Vaccine, Boostrix, for Adults
May  3, 2005Approval  Boostrix GlaxoSmithKline Biologicals - Treatment for Prevention of Diphtheria, Tetanus & Pertussis in Adolescents
Mar 15, 2005GlaxoSmithKline Receives Unanimous Favorable Recommendation by FDA Advisory Committee for Boostrix
Jul  7, 2004GlaxoSmithKline Submits Biologics License Application for FDA Approval of Boostrix

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.